DE69841711D1 - Modulator der menschlichen mastzellaktivierung - Google Patents

Modulator der menschlichen mastzellaktivierung

Info

Publication number
DE69841711D1
DE69841711D1 DE69841711T DE69841711T DE69841711D1 DE 69841711 D1 DE69841711 D1 DE 69841711D1 DE 69841711 T DE69841711 T DE 69841711T DE 69841711 T DE69841711 T DE 69841711T DE 69841711 D1 DE69841711 D1 DE 69841711D1
Authority
DE
Germany
Prior art keywords
mast cell
purinoceptors
human
activation
atp binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841711T
Other languages
English (en)
Inventor
Amir Pelleg
Edward B Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scientific Co filed Critical Duska Scientific Co
Application granted granted Critical
Publication of DE69841711D1 publication Critical patent/DE69841711D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
DE69841711T 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung Expired - Lifetime DE69841711D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (1)

Publication Number Publication Date
DE69841711D1 true DE69841711D1 (de) 2010-07-22

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841711T Expired - Lifetime DE69841711D1 (de) 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung

Country Status (9)

Country Link
US (2) US6372724B1 (de)
EP (1) EP1011686B9 (de)
JP (1) JP2001518118A (de)
AT (1) ATE470441T1 (de)
AU (1) AU741713B2 (de)
CA (1) CA2288821C (de)
DE (1) DE69841711D1 (de)
DK (1) DK1011686T3 (de)
WO (1) WO1998042353A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
EP1187617B1 (de) 1999-06-18 2004-03-03 Alcon Manufacturing Ltd. Methode zur konzentrationsbestimmung einer amphipathischen antihistaminischen verbindung durch bestimmung ihrer oberflächen aktivitäts einstufung
GB9916757D0 (en) * 1999-07-17 1999-09-15 Glaxo Group Ltd Method
JP2003528317A (ja) * 2000-03-23 2003-09-24 ノバルティス アクチエンゲゼルシャフト 肥満細胞／好塩基球活性化阻害剤の同定
EP1351936A1 (de) * 2001-01-15 2003-10-15 Glaxo Group Limited Arylpiperidin- und arylpiperazinderivate als induktoren der ldl-rezeptorexpression
EP1351937A1 (de) * 2001-01-15 2003-10-15 Glaxo Group Limited Arylpiperidin-derivate als induktoren der ldl-rezeptorexpression
US20040072865A1 (en) * 2001-01-15 2004-04-15 Bouillot Anne Marie Jeanne Aryl piperidine derivatives as inducers of ldl-receptor expression
WO2003039473A2 (en) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US7378492B2 (en) * 2002-02-20 2008-05-27 Incyte Corporation CD40-related receptor that binds CD40L
WO2004015396A2 (en) * 2002-08-13 2004-02-19 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
WO2004033636A2 (en) * 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
US20070009886A1 (en) * 2002-11-12 2007-01-11 Incyte Corporation Carbohydrate-associated proteins
WO2004044165A2 (en) * 2002-11-13 2004-05-27 Incyte Corporation Lipid-associated proteins
WO2004048550A2 (en) * 2002-11-26 2004-06-10 Incyte Corporation Immune response associated proteins
US7829682B1 (en) 2003-04-30 2010-11-09 Incyte Corporation Human β-adrenergic receptor kinase nucleic acid molecule
EP1773405A4 (de) * 2004-07-22 2011-10-05 Duska Scient Co Verfahren zur diagnose, überwachung und behandlung von lungenerkrankungen
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
WO2008113017A2 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2014066830A1 (en) 2012-10-25 2014-05-01 Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
AU2566595A (en) * 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
US5733916A (en) 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation

Also Published As

Publication number Publication date
AU741713B2 (en) 2001-12-06
CA2288821A1 (en) 1998-10-01
EP1011686A4 (de) 2003-03-19
US6465441B2 (en) 2002-10-15
CA2288821C (en) 2008-10-14
US6372724B1 (en) 2002-04-16
DK1011686T3 (da) 2010-10-11
US20020055515A1 (en) 2002-05-09
EP1011686B1 (de) 2010-06-09
WO1998042353A1 (en) 1998-10-01
EP1011686A1 (de) 2000-06-28
EP1011686B9 (de) 2011-02-09
ATE470441T1 (de) 2010-06-15
JP2001518118A (ja) 2001-10-09
AU7098598A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
ATE470441T1 (de) Modulator der menschlichen mastzellaktivierung
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
ATE413386T1 (de) Ppar-gamma modulatoren
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
DE69620458T2 (de) Benzofuran-carboxamide und -sulfonamide
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
WO2002098891A3 (en) GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
DK1185621T3 (da) Overflade til cellekultur
WO2004053144A3 (en) Modulation of stem cell differentiation by modulation of caspase-3 activity
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
NO993546D0 (no) 1,4-dihydropyridinderivater og deres anvendelse i terapi
WO2003033656A3 (en) MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE